Oscar Goodman

Oscar Goodman, MD, PhD, is an Associate Professor of Internal Medicine at Roseman University. His research focuses on prostate cancer biology, drug resistance mechanisms, and health disparities in cancer treatment. He leads studies on CYP3A5's role in androgen receptor signaling and its impact on therapeutic resistance in African American patients. His work integrates molecular pharmacology, clinical trials, and genomic analysis to develop targeted therapies for metastatic castration-resistant prostate cancer (mCRPC).

Key research interests include:

• CYP3A5 inhibition and its effects on prostate cancer cell proliferation
• Clinical trials of novel therapies (e.g., ceralasertib, vudalimab)
• Drug synergy studies combining CDK4/6 inhibitors with other agents
• Biomarker-driven approaches for patient stratification
• Health disparities in prostate cancer outcomes

Recent articles highlight advancements in combination therapies for urothelial carcinoma, renal cell carcinoma, and gynecological malignancies. His work emphasizes translational research bridging basic science and clinical applications.